These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 23331434)

  • 21. [Hypercholesterolemia: when statins are not enough or not tolerated. With combination therapy to LDL cholesterol target goal].
    MMW Fortschr Med; 2012 Jul; 154(13):86-7. PubMed ID: 22957390
    [No Abstract]   [Full Text] [Related]  

  • 22. Comparative efficacy and safety of low-dose pitavastatin versus atorvastatin in patients with hypercholesterolemia.
    Sansanayudh N; Wongwiwatthananukit S; Putwai P; Dhumma-Upakorn R
    Ann Pharmacother; 2010 Mar; 44(3):415-23. PubMed ID: 20179259
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins.
    Tran YB; Frial T; Miller PS
    Can J Clin Pharmacol; 2007; 14(2):e205-14. PubMed ID: 17556788
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
    Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
    Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Ezetimib as combination partner in hypercholesteremia. Lowering LDL beyond the effect of statins].
    Sudhop T; von Bergmann K
    MMW Fortschr Med; 2003 Apr; 145(16):48-50. PubMed ID: 14606402
    [No Abstract]   [Full Text] [Related]  

  • 26. [New treatment option for decreasing blood cholesterol level--clinical significance of inhibition of both, cholesterol absorption and synthesis].
    Paragh G; Márk L; Czine Z
    Orv Hetil; 2004 Apr; 145(15):805-11. PubMed ID: 15188635
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis.
    Cobos A; Jovell AJ; García-Altés A; García-Closas R; Serra-Majem L
    Clin Ther; 1999 Nov; 21(11):1924-36. PubMed ID: 10890264
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin.
    Gazi IF; Daskalopoulou SS; Nair DR; Mikhailidis DP
    Curr Med Res Opin; 2007 Sep; 23(9):2183-92. PubMed ID: 17692154
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Lowering cholesterol: how low is low enough?].
    Czuriga I; Edes I
    Orv Hetil; 2006 Jul; 147(29):1349-56. PubMed ID: 16941825
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An investigative look: selective cholesterol absorption inhibitors--embarking on a new standard of care.
    Stein EA
    Am J Manag Care; 2002 Feb; 8(2 Suppl):S36-9; discussion S45-7. PubMed ID: 11855701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacodynamic interaction between ezetimibe and rosuvastatin.
    Kosoglou T; Statkevich P; Yang B; Suresh R; Zhu Y; Boutros T; Maxwell SE; Tiessen R; Cutler DL
    Curr Med Res Opin; 2004 Aug; 20(8):1185-95. PubMed ID: 15324521
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
    Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T
    Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets?
    Piorkowski M; Fischer S; Stellbaum C; Jaster M; Martus P; Morguet AJ; Schultheiss HP; Rauch U
    J Am Coll Cardiol; 2007 Mar; 49(10):1035-42. PubMed ID: 17349882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term efficacy and safety of a generic atorvastatin in usual clinical care setting.
    Ong LM; Punithavathi N; Lena YL; Mahanim O; Leekha S;
    Med J Malaysia; 2011 Aug; 66(3):214-9. PubMed ID: 22111443
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of rosuvastatin in reducing LDL-C and target LDL-C goal attainment in real-world clinical practice.
    Gandhi SK; Järbrink K; Fox KM; Brandrup-Wognsen G
    Curr Med Res Opin; 2009 Dec; 25(12):2817-28. PubMed ID: 19916726
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia.
    Hilleman DE; Phillips JO; Mohiuddin SM; Ryschon KL; Pedersen CA
    Clin Ther; 1999 Mar; 21(3):536-62. PubMed ID: 10321422
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alternate-day dosing of HMG-CoA reductase inhibitors for cholesterol reduction.
    Metz CA; Lucas KH
    Ann Pharmacother; 2001 Apr; 35(4):496-500. PubMed ID: 11302415
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Statins and low-density lipoprotein cholesterol levels.
    Cohen JS
    Am J Med; 2003 Jul; 115(1):74-5; author reply 75-6. PubMed ID: 12867244
    [No Abstract]   [Full Text] [Related]  

  • 39. Prescribing statins: the real issues.
    Hamilton-Craig IR
    Med J Aust; 2014 May; 200(8):440-1. PubMed ID: 24794593
    [No Abstract]   [Full Text] [Related]  

  • 40. A potential role for monoclonal antibodies in clinical lipidology: can we look beyond statins?
    Kalhan A; Rees A
    Curr Opin Lipidol; 2013 Oct; 24(5):457-8. PubMed ID: 24005222
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.